Skip to main content
. Author manuscript; available in PMC: 2021 Jul 8.
Published in final edited form as: Arthritis Care Res (Hoboken). 2018 Nov 30;71(1):2–29. doi: 10.1002/acr.23789

Figure 1.

Figure 1.

Pharmacologic, nonpharmacologic, and symptomatic therapies for psoriatic arthritis. Pharmacologic therapies are displayed in the blue boxes and include oral small molecules (OSMs), tumor necrosis factor inhibitor (TNFi) biologics, interleukin-17 inhibitor (IL-17i) biologics, an IL-12/23i biologic, CTLA4-immunoglobulin, and a JAK inhibitor. While there are numerous nonpharmacologic therapies available, 6 of these are addressed in this guideline. Symptomatic therapies include nonsteroidal antiinflammatory drugs, systemic glucocorticoids, and local glucocorticoid injections. Systemic glucocorticoids or local injections are not addressed in this guideline.